Cranberry fruit powder × placebo-controlled improvement in objective urinary flow

Required evidence, verification status and materials actually read
Item	AVerification status	BReading scope	CReview item	DCurrent findings	EWhy unverified	FRequired materials and conditions	GFurther research
1	Partly verified	Full text not readStored summary read	N01 · Evidence conditionWhat are the selected objective-flow claim and original verdict?Required	The selected claim is “Placebo-controlled improvement in objective urinary flow,” with original grade “?” and note “Reported changes were mainly within-group comparisons.” Subclaim score, status and axes are unrecorded; parent C46 or IPSS grade C is not inserted. S01 S02	The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.	Distinguishing the subclaim, grade and note from the parent IPSS verdict	Material needed: The stored summary has no separate subclaim score, status, axes or confirmed placebo-controlled urinary-flow effect. This records needed materials; no new research was executed.
2	Partly verified	Full text not readStored summary read	N02 · Evidence conditionAre within-group changes distinguished from placebo contrasts?Required	The text’s Qmax, Qavg and residual-volume changes concern change from baseline in the500mg group, not confirmed placebo contrasts. They are not converted into placebo-controlled efficacy, zero effect or a new failure grade. S01	The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.	Baseline change, between-group estimates, analysis model and uncertainty	Material needed: Exact between-group flow estimates, units, CIs, denominators and models are unverified. This records needed materials; no new research was executed.
3	Partly verified	Full text not readStored summary read	N03 · Evidence conditionWhich population and denominators do the results concern?Required	The Korean text records124 men aged45 or older with IPSS at least8; the English text says aged over45. Both original wordings are preserved. Group or urinary-flow analysis denominators and an objective obstruction diagnosis are not inferred. S01	The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.	Eligibility, age, symptoms, baseline objective values and group denominators	Material needed: Group counts, detailed eligibility, baseline flow/residual volume, diagnoses, completion and analysis counts are unverified. This records needed materials; no new research was executed.
4	Partly verified	Full text not readStored summary read	N04 · Evidence conditionWhat were the test product and two doses?Required	S01 is a six-month trial comparing Flowens™ branded fruit powder250mg/day,500mg/day and placebo in three groups. It is not converted into ordinary cranberry, juice, other PAC products or a urinary-flow treatment dose. S01	The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.	Branded test product, composition, planned dose and actual exposure	Material needed: Product composition, PAC content, actual adherence, exposure distribution and measurement linkage for the500mg group are unverified. This records needed materials; no new research was executed.
5	Partly verified	Full text not readStored summary read	N05 · Evidence conditionWhat were the actual placebo conditions?Required	S01 is a double-blind placebo-controlled trial, but the text records that a confirmed placebo-controlled objective-flow effect was not presented. The design label alone does not verify control conditions, denominators or complete measurement. S01	The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.	Placebo specification, concurrent care and matched objective measurements/denominators	Material needed: Placebo composition/exposure, concurrent care and between-group matching of flow measurements/denominators are unverified. This records needed materials; no new research was executed.
6	Partly verified	Full text not readStored summary read	N06 · Evidence conditionHow was Qmax defined and measured?Required	Qmax is mentioned as an objective outcome in the context of change from baseline in the500mg group. It is not treated as the same measure as IPSS points, Qavg or residual volume. S01	The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.	Maximum-flow definition, units, measurement method and timing	Material needed: Qmax definition, units, measurement method, validity criteria, exact values/CIs and denominators are unverified. This records needed materials; no new research was executed.
7	Partly verified	Full text not readStored summary read	N07 · Evidence conditionWas Qavg distinguished from Qmax?Required	Qavg is an objective outcome mentioned separately from Qmax, in the context of change from baseline in the500mg group. Significance or effects for one measure are not transferred to another flow measure. S01	The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.	Separate mean-flow definition, measurement and original results	Material needed: Qavg definition, units, measurement, exact values/CIs, timing and denominators are unverified. This records needed materials; no new research was executed.
8	Partly verified	Full text not readStored summary read	N08 · Evidence conditionWas residual volume treated as a separate endpoint?Required	Residual volume is a separate objective outcome described as change from baseline in the500mg group. A residual-volume reduction is not transferred to placebo-controlled Qmax/Qavg improvement or prostate-size change. S01	The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.	Residual-volume definition, units, method and between-group results	Material needed: Residual-volume methods, units, exact values/CIs, between-group contrasts and denominators are unverified. This records needed materials; no new research was executed.
9	Unverified	Full text not readStored summary read	N09 · Evidence conditionWhen were the objective endpoints actually measured?Required	The parent trial lasted six months, and evidence-list endpoints are IPSS at three and six months. Exact flow/residual-volume test times and results are not automatically assigned those same times. S01	The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.	Distinguishing three-/six-month IPSS from objective-test timing	Material needed: Individual Qmax, Qavg and residual-volume times, missing measurements and follow-up windows are unverified. This records needed materials; no new research was executed.
10	Partly verified	Full text not readStored summary read	N10 · Evidence conditionWhat was the500mg group’s change from baseline?Required	The text says changes from baseline were reported in the500mg group. This is not converted into the same result for250mg/placebo or into a placebo difference. S01	The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.	Original within-group values, change, P values, denominators and definitions	Material needed: Baseline/follow-up values, within-group changes/CIs/P values, denominators and adjustment are unverified. This records needed materials; no new research was executed.
11	Partly verified	Full text not readStored summary read	N11 · Evidence conditionAre IPSS results being transferred to objective flow?Required	Six-month IPSS changes−3.1/−4.1/−1.5 points, historical approximate placebo differences−1.6/−2.6 points and dose-specific P values are symptom results. Their values/significance are not transferred to flow/residual-volume effects, CIs or units. S01	The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.	Directness of subjective symptom scales versus objective tests	Material needed: Individual IPSS–objective-flow correspondence and between-group objective effects are not linked. This records needed materials; no new research was executed.
12	Unverified	Full text not readStored summary read	N12 · Evidence conditionWhat are the dose-pattern and other-group gaps?Required	An apparent IPSS dose pattern does not prove an objective-flow dose response. Within-group500mg change is not used as an optimal dose or as evidence of failure/success in other groups. S01	The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.	Objective outcomes and direct contrasts for250mg,500mg and placebo	Material needed: Objective values, direct contrasts, CIs and prespecified models for250mg,500mg and placebo are unverified. This records needed materials; no new research was executed.
13	Unverified	Full text not readStored summary read	N13 · Evidence conditionWhat were the objective-test denominators and missing data?Required	The overall124 participants and three groups are not used as denominators for every flow/residual-volume test or as proof of complete follow-up. Groups, times and tests are not summed as independent participants or trials. S01	The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.	Participant, test, time-point and repeated-measure denominators	Material needed: Valid tests, missing/excluded observations, repeated-measure counts and correlations by group/time are unverified. This records needed materials; no new research was executed.
14	Unverified	Full text not readStored summary read	N14 · Evidence conditionWas measurement standardized?Required	The label “objective urinary flow” alone does not confirm identical measurement conditions, equipment, test volumes, repetition or validity criteria. S01	The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.	Test conditions, equipment, validity criteria and repeatability	Material needed: Measurement conditions, equipment, valid-test criteria and repeatability by group/time are unverified. This records needed materials; no new research was executed.
15	Partly verified	Full text not readStored summary read	N15 · Evidence conditionHow were assessors and analysts masked?Required	The original trial was double-blind and placebo-controlled. Objective testing alone does not verify assessor/analyst masking, product recognition or test standardization. S01	The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.	Objective measurement, actual masking and awareness of conditions	Material needed: Who was masked, masking maintenance, analyst involvement and expectation/contact differences are unverified. This records needed materials; no new research was executed.
16	Partly verified	Full text not readStored summary read	N16 · Evidence conditionHow were allocation and the three-group comparison conducted?Required	The three-group randomized design is preserved, but a report of within-group change alone is not converted into an estimate from a randomized between-group comparison. S01	The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.	Randomization, allocation concealment, baseline objective values and analysis	Material needed: Sequence generation/concealment, balance in baseline objective values, between-group adjustment and models are unverified. This records needed materials; no new research was executed.
17	Unverified	Full text not readStored summary read	N17 · Evidence conditionHow were completion, attrition and ITT/PP handled?Required	The summary records124 participants without linked completion/attrition counts. IPSS or urinary-flow ITT/PP, missing-data handling and complete-participant analysis are not filled in. S01	The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.	Objective-endpoint analysis populations, discontinuation and missing-data handling	Material needed: Group attrition, missing tests, ITT/PP, exclusions, imputation and sensitivity analyses are unverified. This records needed materials; no new research was executed.
18	Unverified	Full text not readStored summary read	N18 · Evidence conditionWhat concurrent treatment, medicines and adherence were recorded?Required	The three-group powder/placebo comparison does not establish that actual product adherence, concurrent urinary management, medicines and lifestyle changes were all verified. S01	The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.	Linking objective tests to concurrent exposures	Material needed: Group records of concurrent treatment, medicines, lifestyle/baseline changes, adherence and discontinuation are unverified. This records needed materials; no new research was executed.
19	Unverified	Full text not readStored summary read	N19 · Evidence conditionWhat was the hierarchy of prespecified IPSS and objective endpoints?Required	The parent’s prespecified-IPSS wording is not expanded into confirmation that Qmax/Qavg/residual volume were prespecified primary endpoints or planned between-group analyses. Unverified registration and the absent registration-identifier field are preserved. S01	The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.	Registration, protocol, SAP and endpoint-/time-specific plans	Material needed: Objective-endpoint hierarchy, group contrasts, multiplicity, pre-recruitment plans, original registration and amendment history are unread. This records needed materials; no new research was executed.
20	Partly verified	Full text not readStored summary read	N20 · Evidence conditionWhich measure’s threshold does the MID material concern?Required	S02 Blanker2019 concerns observational-cohort IPSS/OABQ thresholds. The text’s approximate3.1–5.2 points and citation values5.2 overall/3.2 moderate are preserved separately, not used as flow/residual-volume thresholds or effects. S01 S02	The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.	Distinguishing IPSS symptom thresholds from urinary-flow relevance	Material needed: Objective-flow relevance criteria and direct correspondence with symptom thresholds are unverified. This records needed materials; no new research was executed.
21	Partly verified	Full text not readStored summary read	N21 · Evidence conditionHow are the same trial, cohorts and time points related?Required	S01 Vidlar2016’s124 participants, three groups, multiple times and two selected sheets share one trial. The S02 observational MID cohort is not urinary-flow/cranberry efficacy replication and is not added as new unique trials or participants. S01 S02	The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.	Overlap among the efficacy trial, threshold cohort and two sheets	Material needed: Separate replication under the same flow-comparison conditions and independence of study families are not linked. This records needed materials; no new research was executed.
22	Unverified	Full text not readStored summary read	N22 · Evidence conditionCan the six-month results extend to longer periods or other populations?Required	The parent trial lasted six months, while exact objective-test times remain unlinked. Placebo-controlled flow effects are not generalized to other ages/diagnoses or repeated/long-term exposure. S01	The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.	Exact objective-test timing, persistence and population-specific direct material	Material needed: Long-term persistence, population-specific objective effects/denominators and safety are not linked. This records needed materials; no new research was executed.
23	Partly verified	Full text not readStored summary read	N23 · Evidence conditionAre prostate size, clinical treatment and ordinary products distinguished?Required	The parent text records that definite prostate-shrinkage or stronger-flow claims exceed scope. Within-group flow/symptom signals are not converted into prostate treatment, prevention, replacement of standard treatment, or effects of ordinary juice/other PAC products. S01	The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.	Directness for objective measures versus other questions/products	Material needed: Direct material for other clinical questions, products and treatment-replacement comparisons is not linked. This records needed materials; no new research was executed.
24	Partly verified	Full text not readStored summary read	N24 · Evidence conditionWhat manufacturer employment, support and interests were recorded?Required	The record of two Naturex-employed authors and a branded test product is preserved. This does not substitute for complete funding, free support or COI verification, or a urinary-flow verdict. S02 cohort support is separately unverified. S01 S02	The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.	Original employment, product, funding and research-role material	Material needed: Funding roles, product support, employee-author contributions, COI and supporting-cohort support are unverified. This records needed materials; no new research was executed.
25	Unverified	Full text not readStored summary read	N25 · Harm-information gaps supplementing the efficacy tableWhat gaps concern safety, laboratory tests and interactions?Supplementary	Parent safety “Unknown” and no six-month clinical-chemistry/hematology change are original statements. No laboratory change is not converted into zero harm or long-term safety; possible warfarin/other interactions are preserved only in their original context. S01	The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.	Adverse events, laboratory tests, exposure, denominators and discontinuation	Material needed: Direct material on event collection/definitions, group denominators, discontinuation, rare harms and interactions is unverified. This records needed materials; no new research was executed.
26	Partly verified	Full text not readStored summary read	N26 · Evidence conditionWere original values, axes, bilingual text, dates and history preserved?Required	Parent C46, B/P/R1/I0/E~/B1, unrecorded precision, four false flags, empty override reasons, and subclaim “?”/note are preserved. Bilingual text,2026-09-07, empty corrections/deliberation and historical effect/scoring checks are not inherited as current review or subclaim scores. S01 S02	The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.	Distinguishing parent C46, subclaim “?”, corrections and historical checks	Material needed: Subclaim score/status/axes, new corrections and external details of historical checks are unverified. This records needed materials; no new research was executed.
27	Partly verified	Full text not readStored summary read	N27 · Evidence conditionWhat was actually read, and what follow-up material is needed?Required	S01 efficacy/objective-outcome statements and the S02 MID citation were used for production, retaining original links. External abstracts, full texts, registration, protocols, SAPs and COI material are unread and were not accessed. S01 S02	The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.	Stored-summary use, unread external material and update scope	Material needed: Report-specific originals, registration, plans, support material, actual external reading and follow-up content review remain incomplete. This records needed materials; no new research was executed.

No items match your search or filter.

27 itemsWhat the statuses mean

Assessment scope

Stored-material review date: Not recorded
Original evidence cut-off: 2026-09-07
Scope actually checked: Existing review summaries and stored records of methodological application. Full papers, supplements, registrations, plans and original data were not read.
What the dates mean: This is the date the stored materials were checked, not the date of a new search of the clinical literature.
Population: The Korean text records124 men aged45 or older with IPSS at least8; the English text says aged over45. Group-/objective-test-specific denominators, baseline flow/residual volume, diagnoses and attrition are unverified.
Ingredient, formulation and route: Three groups received Flowens™ branded fruit powder250mg/day,500mg/day or placebo. Objective outcomes are described as changes from baseline in the500mg group; composition, PAC content and actual adherence are unverified.
Dose: 250/500mg/day and six months are research-exposure records. No urinary-flow dose response, optimal dose, ordinary-product equivalence, recommended intake or conversion is created.
Comparator: The trial was placebo-controlled, but reported objective changes mainly concern baseline comparisons in the500mg group. Exact between-group effects, CIs and control-measurement conditions for Qmax, Qavg and residual volume are unverified.
Measured outcome: Placebo-controlled objective-flow improvement retains original grade? and the note that comparisons were mainly within-group. Individual Qmax/Qavg/residual-volume definitions, units, values, times, denominators and between-group effects are unverified. IPSS changes, approximate group differences, P values and MIDs are not transferred to objective effects or units.
Duration: Distinguish the parent six-month trial and evidence-list three-/six-month IPSS from exact objective-test timing. Long-term persistence and direct flow effects in other populations/products are not linked.
Questions outside this scope: Transferring500mg baseline objective changes to confirmed placebo effects/CIs or250mg results; Mixing Qmax, Qavg or residual-volume units, times and denominators, or transferring IPSS/MID values to flow effects; Converting an unconfirmed placebo comparison with original grade? into zero effect, a new failure grade or definite harm; Using the overall124 participants, groups, times or tests as objective-test denominators, complete follow-up or independent participant totals; Using the supporting observational MID cohort as independent cranberry/urinary-flow efficacy replication; Transferring the test product/exposure to ordinary products, optimal doses or treatment replacement, or creating new arithmetic, effects, CIs, grades, hypothetical numbers, intake, urinary/prostate treatment, prevention or replacement advice

Evidence and sources

The links below lead to the sources. A link alone does not mean the original source was read or its latest publication status verified.

S01 · Vidlar A et al. 2016

PubMed

Material type: Three-arm double-blind randomized placebo-controlled trial
Materials actually read: Summary read; external material unread
Findings recorded in the stored summary: Six-month changes−3.1 points (250mg),−4.1 points (500mg),−1.5 points (placebo)
Record level: Original efficacy summary; group changes distinguished from placebo differences
Study overlap and independent replication: The Vidlar2016 Flowens trial of124 participants, three groups and3/6 months is shared by two sheets. Group IPSS changes, historical approximate placebo contrasts and objective-flow/residual-urine changes from baseline in the500mg group are distinguished. Blanker2019 is a supporting observational MID cohort, not cranberry efficacy replication. Textual3.1–5.2 and citation values5.2 overall/3.2 moderate are preserved separately. The same participants, groups, times, sheets and supporting citations are not newly added as unique trials or participant totals. Confirmed unique-trial, participant and independent-replication totals remain unrecorded.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored summary	Stored file	Stored summary	Summary read	Only stored-summary and bibliographic content was used for production. External material verification/review is not complete.
External paper	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Registration material	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Protocol	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Statistical analysis plan	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Funding, product-support and COI material	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.

S02 · Blanker MH, et al. Determining the minimal important differences in the International Prostate Symptom Score and Overactive Bladder Questionnaire: results from an observational cohort study in Dutch primary care. BMJ Open. 2019;9:e032795. PMID: 31874883. PMCID: PMC7008409. DOI: 10.1136/bmjopen-2019-032795.

PubMed

Material type: Observational-cohort minimal important-difference estimate; supporting citation
Materials actually read: Summary read; external material unread
Findings recorded in the stored summary: Patient-anchored IPSS minimal important differences were estimated at approximately5.2 points overall and3.2 for moderate symptoms.
Record level: Observational-cohort MID citation summary; not an efficacy result
Study overlap and independent replication: The Vidlar2016 Flowens trial of124 participants, three groups and3/6 months is shared by two sheets. Group IPSS changes, historical approximate placebo contrasts and objective-flow/residual-urine changes from baseline in the500mg group are distinguished. Blanker2019 is a supporting observational MID cohort, not cranberry efficacy replication. Textual3.1–5.2 and citation values5.2 overall/3.2 moderate are preserved separately. The same participants, groups, times, sheets and supporting citations are not newly added as unique trials or participant totals. Confirmed unique-trial, participant and independent-replication totals remain unrecorded.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored summary	Stored file	Stored summary	Summary read	Only stored-summary and bibliographic content was used for production. External material verification/review is not complete.
External paper	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Registration material	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Protocol	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Statistical analysis plan	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Funding, product-support and COI material	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.

Report counts versus independent study counts

The Vidlar2016 Flowens trial of124 participants, three groups and3/6 months is shared by two sheets. Group IPSS changes, historical approximate placebo contrasts and objective-flow/residual-urine changes from baseline in the500mg group are distinguished. Blanker2019 is a supporting observational MID cohort, not cranberry efficacy replication. Textual3.1–5.2 and citation values5.2 overall/3.2 moderate are preserved separately. The same participants, groups, times, sheets and supporting citations are not newly added as unique trials or participant totals. Confirmed unique-trial, participant and independent-replication totals remain unrecorded.

Review criteria

Version 1.0 · Criteria record date 2026-10-06. These are Chamgap's own application conditions, informed by the referenced methods. They do not constitute official assessment-tool certification or a new efficacy score.

N01 · What are the selected objective-flow claim and original verdict?

Required materials and conditions: Distinguishing the subclaim, grade and note from the parent IPSS verdict
Conditions for verification: Material for Distinguishing the subclaim, grade and note from the parent IPSS verdict must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Requirement and applicability: Required
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Why this condition is needed: This condition connects Distinguishing the subclaim, grade and note from the parent IPSS verdict with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

N02 · Are within-group changes distinguished from placebo contrasts?

Required materials and conditions: Baseline change, between-group estimates, analysis model and uncertainty
Conditions for verification: Material for Baseline change, between-group estimates, analysis model and uncertainty must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Requirement and applicability: Required
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Why this condition is needed: This condition connects Baseline change, between-group estimates, analysis model and uncertainty with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

N03 · Which population and denominators do the results concern?

Required materials and conditions: Eligibility, age, symptoms, baseline objective values and group denominators
Conditions for verification: Material for Eligibility, age, symptoms, baseline objective values and group denominators must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Requirement and applicability: Required
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Why this condition is needed: This condition connects Eligibility, age, symptoms, baseline objective values and group denominators with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

N04 · What were the test product and two doses?

Required materials and conditions: Branded test product, composition, planned dose and actual exposure
Conditions for verification: Material for Branded test product, composition, planned dose and actual exposure must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Requirement and applicability: Required
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Why this condition is needed: This condition connects Branded test product, composition, planned dose and actual exposure with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

N05 · What were the actual placebo conditions?

Required materials and conditions: Placebo specification, concurrent care and matched objective measurements/denominators
Conditions for verification: Material for Placebo specification, concurrent care and matched objective measurements/denominators must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Requirement and applicability: Required
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Why this condition is needed: This condition connects Placebo specification, concurrent care and matched objective measurements/denominators with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

N06 · How was Qmax defined and measured?

Required materials and conditions: Maximum-flow definition, units, measurement method and timing
Conditions for verification: Material for Maximum-flow definition, units, measurement method and timing must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Requirement and applicability: Required
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Why this condition is needed: This condition connects Maximum-flow definition, units, measurement method and timing with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

N07 · Was Qavg distinguished from Qmax?

Required materials and conditions: Separate mean-flow definition, measurement and original results
Conditions for verification: Material for Separate mean-flow definition, measurement and original results must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Requirement and applicability: Required
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Why this condition is needed: This condition connects Separate mean-flow definition, measurement and original results with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

N08 · Was residual volume treated as a separate endpoint?

Required materials and conditions: Residual-volume definition, units, method and between-group results
Conditions for verification: Material for Residual-volume definition, units, method and between-group results must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Requirement and applicability: Required
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Why this condition is needed: This condition connects Residual-volume definition, units, method and between-group results with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

N09 · When were the objective endpoints actually measured?

Required materials and conditions: Distinguishing three-/six-month IPSS from objective-test timing
Conditions for verification: Material for Distinguishing three-/six-month IPSS from objective-test timing must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Requirement and applicability: Required
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Why this condition is needed: This condition connects Distinguishing three-/six-month IPSS from objective-test timing with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

N10 · What was the500mg group’s change from baseline?

Required materials and conditions: Original within-group values, change, P values, denominators and definitions
Conditions for verification: Material for Original within-group values, change, P values, denominators and definitions must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Requirement and applicability: Required
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Why this condition is needed: This condition connects Original within-group values, change, P values, denominators and definitions with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

N11 · Are IPSS results being transferred to objective flow?

Required materials and conditions: Directness of subjective symptom scales versus objective tests
Conditions for verification: Material for Directness of subjective symptom scales versus objective tests must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Requirement and applicability: Required
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Why this condition is needed: This condition connects Directness of subjective symptom scales versus objective tests with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

N12 · What are the dose-pattern and other-group gaps?

Required materials and conditions: Objective outcomes and direct contrasts for250mg,500mg and placebo
Conditions for verification: Material for Objective outcomes and direct contrasts for250mg,500mg and placebo must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Requirement and applicability: Required
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Why this condition is needed: This condition connects Objective outcomes and direct contrasts for250mg,500mg and placebo with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

N13 · What were the objective-test denominators and missing data?

Required materials and conditions: Participant, test, time-point and repeated-measure denominators
Conditions for verification: Material for Participant, test, time-point and repeated-measure denominators must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Requirement and applicability: Required
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Why this condition is needed: This condition connects Participant, test, time-point and repeated-measure denominators with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

N14 · Was measurement standardized?

Required materials and conditions: Test conditions, equipment, validity criteria and repeatability
Conditions for verification: Material for Test conditions, equipment, validity criteria and repeatability must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Requirement and applicability: Required
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Why this condition is needed: This condition connects Test conditions, equipment, validity criteria and repeatability with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

N15 · How were assessors and analysts masked?

Required materials and conditions: Objective measurement, actual masking and awareness of conditions
Conditions for verification: Material for Objective measurement, actual masking and awareness of conditions must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Requirement and applicability: Required
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Why this condition is needed: This condition connects Objective measurement, actual masking and awareness of conditions with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

N16 · How were allocation and the three-group comparison conducted?

Required materials and conditions: Randomization, allocation concealment, baseline objective values and analysis
Conditions for verification: Material for Randomization, allocation concealment, baseline objective values and analysis must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Requirement and applicability: Required
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Why this condition is needed: This condition connects Randomization, allocation concealment, baseline objective values and analysis with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

N17 · How were completion, attrition and ITT/PP handled?

Required materials and conditions: Objective-endpoint analysis populations, discontinuation and missing-data handling
Conditions for verification: Material for Objective-endpoint analysis populations, discontinuation and missing-data handling must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Requirement and applicability: Required
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Why this condition is needed: This condition connects Objective-endpoint analysis populations, discontinuation and missing-data handling with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

N18 · What concurrent treatment, medicines and adherence were recorded?

Required materials and conditions: Linking objective tests to concurrent exposures
Conditions for verification: Material for Linking objective tests to concurrent exposures must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Requirement and applicability: Required
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Why this condition is needed: This condition connects Linking objective tests to concurrent exposures with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

N19 · What was the hierarchy of prespecified IPSS and objective endpoints?

Required materials and conditions: Registration, protocol, SAP and endpoint-/time-specific plans
Conditions for verification: Material for Registration, protocol, SAP and endpoint-/time-specific plans must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Requirement and applicability: Required
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Why this condition is needed: This condition connects Registration, protocol, SAP and endpoint-/time-specific plans with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

N20 · Which measure’s threshold does the MID material concern?

Required materials and conditions: Distinguishing IPSS symptom thresholds from urinary-flow relevance
Conditions for verification: Material for Distinguishing IPSS symptom thresholds from urinary-flow relevance must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Requirement and applicability: Required
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Why this condition is needed: This condition connects Distinguishing IPSS symptom thresholds from urinary-flow relevance with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

N21 · How are the same trial, cohorts and time points related?

Required materials and conditions: Overlap among the efficacy trial, threshold cohort and two sheets
Conditions for verification: Material for Overlap among the efficacy trial, threshold cohort and two sheets must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Requirement and applicability: Required
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Why this condition is needed: This condition connects Overlap among the efficacy trial, threshold cohort and two sheets with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

N22 · Can the six-month results extend to longer periods or other populations?

Required materials and conditions: Exact objective-test timing, persistence and population-specific direct material
Conditions for verification: Material for Exact objective-test timing, persistence and population-specific direct material must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Requirement and applicability: Required
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Why this condition is needed: This condition connects Exact objective-test timing, persistence and population-specific direct material with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

N23 · Are prostate size, clinical treatment and ordinary products distinguished?

Required materials and conditions: Directness for objective measures versus other questions/products
Conditions for verification: Material for Directness for objective measures versus other questions/products must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Requirement and applicability: Required
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Why this condition is needed: This condition connects Directness for objective measures versus other questions/products with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

N24 · What manufacturer employment, support and interests were recorded?

Required materials and conditions: Original employment, product, funding and research-role material
Conditions for verification: Material for Original employment, product, funding and research-role material must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Requirement and applicability: Required
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Why this condition is needed: This condition connects Original employment, product, funding and research-role material with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

N25 · What gaps concern safety, laboratory tests and interactions?

Required materials and conditions: Adverse events, laboratory tests, exposure, denominators and discontinuation
Conditions for verification: Material for Adverse events, laboratory tests, exposure, denominators and discontinuation must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Requirement and applicability: Supplementary
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Why this condition is needed: This condition connects Adverse events, laboratory tests, exposure, denominators and discontinuation with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

N26 · Were original values, axes, bilingual text, dates and history preserved?

Required materials and conditions: Distinguishing parent C46, subclaim “?”, corrections and historical checks
Conditions for verification: Material for Distinguishing parent C46, subclaim “?”, corrections and historical checks must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Requirement and applicability: Required
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Why this condition is needed: This condition connects Distinguishing parent C46, subclaim “?”, corrections and historical checks with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

N27 · What was actually read, and what follow-up material is needed?

Required materials and conditions: Stored-summary use, unread external material and update scope
Conditions for verification: Material for Stored-summary use, unread external material and update scope must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Requirement and applicability: Required
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Why this condition is needed: This condition connects Stored-summary use, unread external material and update scope with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

Referenced methods and the sections actually reviewed

M03 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13

Referenced principle: Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

M04 · Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03

Official methodology · §4.5, §4.6.1–4.6.3, MECIR C42

Referenced principle: Distinguish studies from reports and link them; do not omit a study solely because results are unreported.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

M08 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §8.1–8.2.3, Table 8.2.a

Referenced principle: Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

M15 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §15.2.4, §15.3.1–15.3.3

Referenced principle: Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

M19 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §19.1.2, §19.2.1–19.2.4

Referenced principle: Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

What the statuses mean

Met: Status for necessary evidence confirmed after existing content review. No completion is declared in the current presentation.
Partly verified: Some information in the stored summary is linked into the table. External comparison/content review is not complete.
Unverified: The article leaves this unverified, or required material is absent from the current stored summary. This is distinct from zero, absence or safety.
Review incomplete: Existing content review remains incomplete.
Not reported: Not reported within the stored material actually read; not extended to the entire primary paper.
Inaccessible: Means an actual access failure. Access not attempted here is not assigned this state.
Not applicable: Not used as a substitute for an evidence gap.
Conflicting data: Requires an observed disagreement under the same comparison criteria; not automatically judged in this production.
Insufficient evidence for the conditions: Marks a gap in additional material required by the selected conditions; not a new efficacy grade.

Change history

2026-10-16 · Public page/material version 1.0

Public pages and materials were prepared from the existing 27 items. No new clinical search, verification-status change or scoring was performed.

The stored-material review date (Not recorded) and original evidence cut-off (2026-09-07) were retained unchanged.

Researcher downloads

These materials provide the same evidence, scope and verification status as this page.

View all item details

N01 · What are the selected objective-flow claim and original verdict?

Current findings: The selected claim is “Placebo-controlled improvement in objective urinary flow,” with original grade “?” and note “Reported changes were mainly within-group comparisons.” Subclaim score, status and axes are unrecorded; parent C46 or IPSS grade C is not inserted.
Verification status: Partly verified
Materials actually read: Stored summary read; external abstracts, full texts, registration, protocols and SAPs unread
Why unverified: The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.
Reason for missing information: The stored summary has no separate subclaim score, status, axes or confirmed placebo-controlled urinary-flow effect.
Required materials and conditions: Distinguishing the subclaim, grade and note from the parent IPSS verdict
Materials to obtain first: The stored summary has no separate subclaim score, status, axes or confirmed placebo-controlled urinary-flow effect.
Further research: Material needed: The stored summary has no separate subclaim score, status, axes or confirmed placebo-controlled urinary-flow effect. This records needed materials; no new research was executed.
Remaining uncertainty: External original material is unread and review of existing content remains incomplete. Original grades, scores, axes, historical verification and independence statements are not treated as new verdicts or certification.
Conditions for verification: Material for Distinguishing the subclaim, grade and note from the parent IPSS verdict must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Why this condition is needed: This condition connects Distinguishing the subclaim, grade and note from the parent IPSS verdict with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

Related sources S01 S02

N02 · Are within-group changes distinguished from placebo contrasts?

Current findings: The text’s Qmax, Qavg and residual-volume changes concern change from baseline in the500mg group, not confirmed placebo contrasts. They are not converted into placebo-controlled efficacy, zero effect or a new failure grade.
Verification status: Partly verified
Materials actually read: Stored summary read; external abstracts, full texts, registration, protocols and SAPs unread
Why unverified: The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.
Reason for missing information: Exact between-group flow estimates, units, CIs, denominators and models are unverified.
Required materials and conditions: Baseline change, between-group estimates, analysis model and uncertainty
Materials to obtain first: Exact between-group flow estimates, units, CIs, denominators and models are unverified.
Further research: Material needed: Exact between-group flow estimates, units, CIs, denominators and models are unverified. This records needed materials; no new research was executed.
Remaining uncertainty: External original material is unread and review of existing content remains incomplete. Original grades, scores, axes, historical verification and independence statements are not treated as new verdicts or certification.
Conditions for verification: Material for Baseline change, between-group estimates, analysis model and uncertainty must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Why this condition is needed: This condition connects Baseline change, between-group estimates, analysis model and uncertainty with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

Related sources S01

N03 · Which population and denominators do the results concern?

Current findings: The Korean text records124 men aged45 or older with IPSS at least8; the English text says aged over45. Both original wordings are preserved. Group or urinary-flow analysis denominators and an objective obstruction diagnosis are not inferred.
Verification status: Partly verified
Materials actually read: Stored summary read; external abstracts, full texts, registration, protocols and SAPs unread
Why unverified: The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.
Reason for missing information: Group counts, detailed eligibility, baseline flow/residual volume, diagnoses, completion and analysis counts are unverified.
Required materials and conditions: Eligibility, age, symptoms, baseline objective values and group denominators
Materials to obtain first: Group counts, detailed eligibility, baseline flow/residual volume, diagnoses, completion and analysis counts are unverified.
Further research: Material needed: Group counts, detailed eligibility, baseline flow/residual volume, diagnoses, completion and analysis counts are unverified. This records needed materials; no new research was executed.
Remaining uncertainty: External original material is unread and review of existing content remains incomplete. Original grades, scores, axes, historical verification and independence statements are not treated as new verdicts or certification.
Conditions for verification: Material for Eligibility, age, symptoms, baseline objective values and group denominators must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Why this condition is needed: This condition connects Eligibility, age, symptoms, baseline objective values and group denominators with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

Related sources S01

N04 · What were the test product and two doses?

Current findings: S01 is a six-month trial comparing Flowens™ branded fruit powder250mg/day,500mg/day and placebo in three groups. It is not converted into ordinary cranberry, juice, other PAC products or a urinary-flow treatment dose.
Verification status: Partly verified
Materials actually read: Stored summary read; external abstracts, full texts, registration, protocols and SAPs unread
Why unverified: The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.
Reason for missing information: Product composition, PAC content, actual adherence, exposure distribution and measurement linkage for the500mg group are unverified.
Required materials and conditions: Branded test product, composition, planned dose and actual exposure
Materials to obtain first: Product composition, PAC content, actual adherence, exposure distribution and measurement linkage for the500mg group are unverified.
Further research: Material needed: Product composition, PAC content, actual adherence, exposure distribution and measurement linkage for the500mg group are unverified. This records needed materials; no new research was executed.
Remaining uncertainty: External original material is unread and review of existing content remains incomplete. Original grades, scores, axes, historical verification and independence statements are not treated as new verdicts or certification.
Conditions for verification: Material for Branded test product, composition, planned dose and actual exposure must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Why this condition is needed: This condition connects Branded test product, composition, planned dose and actual exposure with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

Related sources S01

N05 · What were the actual placebo conditions?

Current findings: S01 is a double-blind placebo-controlled trial, but the text records that a confirmed placebo-controlled objective-flow effect was not presented. The design label alone does not verify control conditions, denominators or complete measurement.
Verification status: Partly verified
Materials actually read: Stored summary read; external abstracts, full texts, registration, protocols and SAPs unread
Why unverified: The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.
Reason for missing information: Placebo composition/exposure, concurrent care and between-group matching of flow measurements/denominators are unverified.
Required materials and conditions: Placebo specification, concurrent care and matched objective measurements/denominators
Materials to obtain first: Placebo composition/exposure, concurrent care and between-group matching of flow measurements/denominators are unverified.
Further research: Material needed: Placebo composition/exposure, concurrent care and between-group matching of flow measurements/denominators are unverified. This records needed materials; no new research was executed.
Remaining uncertainty: External original material is unread and review of existing content remains incomplete. Original grades, scores, axes, historical verification and independence statements are not treated as new verdicts or certification.
Conditions for verification: Material for Placebo specification, concurrent care and matched objective measurements/denominators must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Why this condition is needed: This condition connects Placebo specification, concurrent care and matched objective measurements/denominators with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

Related sources S01

N06 · How was Qmax defined and measured?

Current findings: Qmax is mentioned as an objective outcome in the context of change from baseline in the500mg group. It is not treated as the same measure as IPSS points, Qavg or residual volume.
Verification status: Partly verified
Materials actually read: Stored summary read; external abstracts, full texts, registration, protocols and SAPs unread
Why unverified: The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.
Reason for missing information: Qmax definition, units, measurement method, validity criteria, exact values/CIs and denominators are unverified.
Required materials and conditions: Maximum-flow definition, units, measurement method and timing
Materials to obtain first: Qmax definition, units, measurement method, validity criteria, exact values/CIs and denominators are unverified.
Further research: Material needed: Qmax definition, units, measurement method, validity criteria, exact values/CIs and denominators are unverified. This records needed materials; no new research was executed.
Remaining uncertainty: External original material is unread and review of existing content remains incomplete. Original grades, scores, axes, historical verification and independence statements are not treated as new verdicts or certification.
Conditions for verification: Material for Maximum-flow definition, units, measurement method and timing must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Why this condition is needed: This condition connects Maximum-flow definition, units, measurement method and timing with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

Related sources S01

N07 · Was Qavg distinguished from Qmax?

Current findings: Qavg is an objective outcome mentioned separately from Qmax, in the context of change from baseline in the500mg group. Significance or effects for one measure are not transferred to another flow measure.
Verification status: Partly verified
Materials actually read: Stored summary read; external abstracts, full texts, registration, protocols and SAPs unread
Why unverified: The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.
Reason for missing information: Qavg definition, units, measurement, exact values/CIs, timing and denominators are unverified.
Required materials and conditions: Separate mean-flow definition, measurement and original results
Materials to obtain first: Qavg definition, units, measurement, exact values/CIs, timing and denominators are unverified.
Further research: Material needed: Qavg definition, units, measurement, exact values/CIs, timing and denominators are unverified. This records needed materials; no new research was executed.
Remaining uncertainty: External original material is unread and review of existing content remains incomplete. Original grades, scores, axes, historical verification and independence statements are not treated as new verdicts or certification.
Conditions for verification: Material for Separate mean-flow definition, measurement and original results must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Why this condition is needed: This condition connects Separate mean-flow definition, measurement and original results with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

Related sources S01

N08 · Was residual volume treated as a separate endpoint?

Current findings: Residual volume is a separate objective outcome described as change from baseline in the500mg group. A residual-volume reduction is not transferred to placebo-controlled Qmax/Qavg improvement or prostate-size change.
Verification status: Partly verified
Materials actually read: Stored summary read; external abstracts, full texts, registration, protocols and SAPs unread
Why unverified: The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.
Reason for missing information: Residual-volume methods, units, exact values/CIs, between-group contrasts and denominators are unverified.
Required materials and conditions: Residual-volume definition, units, method and between-group results
Materials to obtain first: Residual-volume methods, units, exact values/CIs, between-group contrasts and denominators are unverified.
Further research: Material needed: Residual-volume methods, units, exact values/CIs, between-group contrasts and denominators are unverified. This records needed materials; no new research was executed.
Remaining uncertainty: External original material is unread and review of existing content remains incomplete. Original grades, scores, axes, historical verification and independence statements are not treated as new verdicts or certification.
Conditions for verification: Material for Residual-volume definition, units, method and between-group results must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Why this condition is needed: This condition connects Residual-volume definition, units, method and between-group results with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

Related sources S01

N09 · When were the objective endpoints actually measured?

Current findings: The parent trial lasted six months, and evidence-list endpoints are IPSS at three and six months. Exact flow/residual-volume test times and results are not automatically assigned those same times.
Verification status: Unverified
Materials actually read: Stored summary read; external abstracts, full texts, registration, protocols and SAPs unread
Why unverified: The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.
Reason for missing information: Individual Qmax, Qavg and residual-volume times, missing measurements and follow-up windows are unverified.
Required materials and conditions: Distinguishing three-/six-month IPSS from objective-test timing
Materials to obtain first: Individual Qmax, Qavg and residual-volume times, missing measurements and follow-up windows are unverified.
Further research: Material needed: Individual Qmax, Qavg and residual-volume times, missing measurements and follow-up windows are unverified. This records needed materials; no new research was executed.
Remaining uncertainty: External original material is unread and review of existing content remains incomplete. Original grades, scores, axes, historical verification and independence statements are not treated as new verdicts or certification.
Conditions for verification: Material for Distinguishing three-/six-month IPSS from objective-test timing must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Why this condition is needed: This condition connects Distinguishing three-/six-month IPSS from objective-test timing with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

Related sources S01

N10 · What was the500mg group’s change from baseline?

Current findings: The text says changes from baseline were reported in the500mg group. This is not converted into the same result for250mg/placebo or into a placebo difference.
Verification status: Partly verified
Materials actually read: Stored summary read; external abstracts, full texts, registration, protocols and SAPs unread
Why unverified: The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.
Reason for missing information: Baseline/follow-up values, within-group changes/CIs/P values, denominators and adjustment are unverified.
Required materials and conditions: Original within-group values, change, P values, denominators and definitions
Materials to obtain first: Baseline/follow-up values, within-group changes/CIs/P values, denominators and adjustment are unverified.
Further research: Material needed: Baseline/follow-up values, within-group changes/CIs/P values, denominators and adjustment are unverified. This records needed materials; no new research was executed.
Remaining uncertainty: External original material is unread and review of existing content remains incomplete. Original grades, scores, axes, historical verification and independence statements are not treated as new verdicts or certification.
Conditions for verification: Material for Original within-group values, change, P values, denominators and definitions must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Why this condition is needed: This condition connects Original within-group values, change, P values, denominators and definitions with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

Related sources S01

N11 · Are IPSS results being transferred to objective flow?

Current findings: Six-month IPSS changes−3.1/−4.1/−1.5 points, historical approximate placebo differences−1.6/−2.6 points and dose-specific P values are symptom results. Their values/significance are not transferred to flow/residual-volume effects, CIs or units.
Verification status: Partly verified
Materials actually read: Stored summary read; external abstracts, full texts, registration, protocols and SAPs unread
Why unverified: The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.
Reason for missing information: Individual IPSS–objective-flow correspondence and between-group objective effects are not linked.
Required materials and conditions: Directness of subjective symptom scales versus objective tests
Materials to obtain first: Individual IPSS–objective-flow correspondence and between-group objective effects are not linked.
Further research: Material needed: Individual IPSS–objective-flow correspondence and between-group objective effects are not linked. This records needed materials; no new research was executed.
Remaining uncertainty: External original material is unread and review of existing content remains incomplete. Original grades, scores, axes, historical verification and independence statements are not treated as new verdicts or certification.
Conditions for verification: Material for Directness of subjective symptom scales versus objective tests must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Why this condition is needed: This condition connects Directness of subjective symptom scales versus objective tests with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

Related sources S01

N12 · What are the dose-pattern and other-group gaps?

Current findings: An apparent IPSS dose pattern does not prove an objective-flow dose response. Within-group500mg change is not used as an optimal dose or as evidence of failure/success in other groups.
Verification status: Unverified
Materials actually read: Stored summary read; external abstracts, full texts, registration, protocols and SAPs unread
Why unverified: The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.
Reason for missing information: Objective values, direct contrasts, CIs and prespecified models for250mg,500mg and placebo are unverified.
Required materials and conditions: Objective outcomes and direct contrasts for250mg,500mg and placebo
Materials to obtain first: Objective values, direct contrasts, CIs and prespecified models for250mg,500mg and placebo are unverified.
Further research: Material needed: Objective values, direct contrasts, CIs and prespecified models for250mg,500mg and placebo are unverified. This records needed materials; no new research was executed.
Remaining uncertainty: External original material is unread and review of existing content remains incomplete. Original grades, scores, axes, historical verification and independence statements are not treated as new verdicts or certification.
Conditions for verification: Material for Objective outcomes and direct contrasts for250mg,500mg and placebo must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Why this condition is needed: This condition connects Objective outcomes and direct contrasts for250mg,500mg and placebo with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

Related sources S01

N13 · What were the objective-test denominators and missing data?

Current findings: The overall124 participants and three groups are not used as denominators for every flow/residual-volume test or as proof of complete follow-up. Groups, times and tests are not summed as independent participants or trials.
Verification status: Unverified
Materials actually read: Stored summary read; external abstracts, full texts, registration, protocols and SAPs unread
Why unverified: The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.
Reason for missing information: Valid tests, missing/excluded observations, repeated-measure counts and correlations by group/time are unverified.
Required materials and conditions: Participant, test, time-point and repeated-measure denominators
Materials to obtain first: Valid tests, missing/excluded observations, repeated-measure counts and correlations by group/time are unverified.
Further research: Material needed: Valid tests, missing/excluded observations, repeated-measure counts and correlations by group/time are unverified. This records needed materials; no new research was executed.
Remaining uncertainty: External original material is unread and review of existing content remains incomplete. Original grades, scores, axes, historical verification and independence statements are not treated as new verdicts or certification.
Conditions for verification: Material for Participant, test, time-point and repeated-measure denominators must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Why this condition is needed: This condition connects Participant, test, time-point and repeated-measure denominators with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

Related sources S01

N14 · Was measurement standardized?

Current findings: The label “objective urinary flow” alone does not confirm identical measurement conditions, equipment, test volumes, repetition or validity criteria.
Verification status: Unverified
Materials actually read: Stored summary read; external abstracts, full texts, registration, protocols and SAPs unread
Why unverified: The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.
Reason for missing information: Measurement conditions, equipment, valid-test criteria and repeatability by group/time are unverified.
Required materials and conditions: Test conditions, equipment, validity criteria and repeatability
Materials to obtain first: Measurement conditions, equipment, valid-test criteria and repeatability by group/time are unverified.
Further research: Material needed: Measurement conditions, equipment, valid-test criteria and repeatability by group/time are unverified. This records needed materials; no new research was executed.
Remaining uncertainty: External original material is unread and review of existing content remains incomplete. Original grades, scores, axes, historical verification and independence statements are not treated as new verdicts or certification.
Conditions for verification: Material for Test conditions, equipment, validity criteria and repeatability must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Why this condition is needed: This condition connects Test conditions, equipment, validity criteria and repeatability with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

Related sources S01

N15 · How were assessors and analysts masked?

Current findings: The original trial was double-blind and placebo-controlled. Objective testing alone does not verify assessor/analyst masking, product recognition or test standardization.
Verification status: Partly verified
Materials actually read: Stored summary read; external abstracts, full texts, registration, protocols and SAPs unread
Why unverified: The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.
Reason for missing information: Who was masked, masking maintenance, analyst involvement and expectation/contact differences are unverified.
Required materials and conditions: Objective measurement, actual masking and awareness of conditions
Materials to obtain first: Who was masked, masking maintenance, analyst involvement and expectation/contact differences are unverified.
Further research: Material needed: Who was masked, masking maintenance, analyst involvement and expectation/contact differences are unverified. This records needed materials; no new research was executed.
Remaining uncertainty: External original material is unread and review of existing content remains incomplete. Original grades, scores, axes, historical verification and independence statements are not treated as new verdicts or certification.
Conditions for verification: Material for Objective measurement, actual masking and awareness of conditions must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Why this condition is needed: This condition connects Objective measurement, actual masking and awareness of conditions with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

Related sources S01

N16 · How were allocation and the three-group comparison conducted?

Current findings: The three-group randomized design is preserved, but a report of within-group change alone is not converted into an estimate from a randomized between-group comparison.
Verification status: Partly verified
Materials actually read: Stored summary read; external abstracts, full texts, registration, protocols and SAPs unread
Why unverified: The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.
Reason for missing information: Sequence generation/concealment, balance in baseline objective values, between-group adjustment and models are unverified.
Required materials and conditions: Randomization, allocation concealment, baseline objective values and analysis
Materials to obtain first: Sequence generation/concealment, balance in baseline objective values, between-group adjustment and models are unverified.
Further research: Material needed: Sequence generation/concealment, balance in baseline objective values, between-group adjustment and models are unverified. This records needed materials; no new research was executed.
Remaining uncertainty: External original material is unread and review of existing content remains incomplete. Original grades, scores, axes, historical verification and independence statements are not treated as new verdicts or certification.
Conditions for verification: Material for Randomization, allocation concealment, baseline objective values and analysis must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Why this condition is needed: This condition connects Randomization, allocation concealment, baseline objective values and analysis with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

Related sources S01

N17 · How were completion, attrition and ITT/PP handled?

Current findings: The summary records124 participants without linked completion/attrition counts. IPSS or urinary-flow ITT/PP, missing-data handling and complete-participant analysis are not filled in.
Verification status: Unverified
Materials actually read: Stored summary read; external abstracts, full texts, registration, protocols and SAPs unread
Why unverified: The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.
Reason for missing information: Group attrition, missing tests, ITT/PP, exclusions, imputation and sensitivity analyses are unverified.
Required materials and conditions: Objective-endpoint analysis populations, discontinuation and missing-data handling
Materials to obtain first: Group attrition, missing tests, ITT/PP, exclusions, imputation and sensitivity analyses are unverified.
Further research: Material needed: Group attrition, missing tests, ITT/PP, exclusions, imputation and sensitivity analyses are unverified. This records needed materials; no new research was executed.
Remaining uncertainty: External original material is unread and review of existing content remains incomplete. Original grades, scores, axes, historical verification and independence statements are not treated as new verdicts or certification.
Conditions for verification: Material for Objective-endpoint analysis populations, discontinuation and missing-data handling must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Why this condition is needed: This condition connects Objective-endpoint analysis populations, discontinuation and missing-data handling with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

Related sources S01

N18 · What concurrent treatment, medicines and adherence were recorded?

Current findings: The three-group powder/placebo comparison does not establish that actual product adherence, concurrent urinary management, medicines and lifestyle changes were all verified.
Verification status: Unverified
Materials actually read: Stored summary read; external abstracts, full texts, registration, protocols and SAPs unread
Why unverified: The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.
Reason for missing information: Group records of concurrent treatment, medicines, lifestyle/baseline changes, adherence and discontinuation are unverified.
Required materials and conditions: Linking objective tests to concurrent exposures
Materials to obtain first: Group records of concurrent treatment, medicines, lifestyle/baseline changes, adherence and discontinuation are unverified.
Further research: Material needed: Group records of concurrent treatment, medicines, lifestyle/baseline changes, adherence and discontinuation are unverified. This records needed materials; no new research was executed.
Remaining uncertainty: External original material is unread and review of existing content remains incomplete. Original grades, scores, axes, historical verification and independence statements are not treated as new verdicts or certification.
Conditions for verification: Material for Linking objective tests to concurrent exposures must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Why this condition is needed: This condition connects Linking objective tests to concurrent exposures with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

Related sources S01

N19 · What was the hierarchy of prespecified IPSS and objective endpoints?

Current findings: The parent’s prespecified-IPSS wording is not expanded into confirmation that Qmax/Qavg/residual volume were prespecified primary endpoints or planned between-group analyses. Unverified registration and the absent registration-identifier field are preserved.
Verification status: Unverified
Materials actually read: Stored summary read; external abstracts, full texts, registration, protocols and SAPs unread
Why unverified: The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.
Reason for missing information: Objective-endpoint hierarchy, group contrasts, multiplicity, pre-recruitment plans, original registration and amendment history are unread.
Required materials and conditions: Registration, protocol, SAP and endpoint-/time-specific plans
Materials to obtain first: Objective-endpoint hierarchy, group contrasts, multiplicity, pre-recruitment plans, original registration and amendment history are unread.
Further research: Material needed: Objective-endpoint hierarchy, group contrasts, multiplicity, pre-recruitment plans, original registration and amendment history are unread. This records needed materials; no new research was executed.
Remaining uncertainty: External original material is unread and review of existing content remains incomplete. Original grades, scores, axes, historical verification and independence statements are not treated as new verdicts or certification.
Conditions for verification: Material for Registration, protocol, SAP and endpoint-/time-specific plans must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Why this condition is needed: This condition connects Registration, protocol, SAP and endpoint-/time-specific plans with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

Related sources S01

N20 · Which measure’s threshold does the MID material concern?

Current findings: S02 Blanker2019 concerns observational-cohort IPSS/OABQ thresholds. The text’s approximate3.1–5.2 points and citation values5.2 overall/3.2 moderate are preserved separately, not used as flow/residual-volume thresholds or effects.
Verification status: Partly verified
Materials actually read: Stored summary read; external abstracts, full texts, registration, protocols and SAPs unread
Why unverified: The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.
Reason for missing information: Objective-flow relevance criteria and direct correspondence with symptom thresholds are unverified.
Required materials and conditions: Distinguishing IPSS symptom thresholds from urinary-flow relevance
Materials to obtain first: Objective-flow relevance criteria and direct correspondence with symptom thresholds are unverified.
Further research: Material needed: Objective-flow relevance criteria and direct correspondence with symptom thresholds are unverified. This records needed materials; no new research was executed.
Remaining uncertainty: External original material is unread and review of existing content remains incomplete. Original grades, scores, axes, historical verification and independence statements are not treated as new verdicts or certification.
Conditions for verification: Material for Distinguishing IPSS symptom thresholds from urinary-flow relevance must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Why this condition is needed: This condition connects Distinguishing IPSS symptom thresholds from urinary-flow relevance with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

Related sources S01 S02

N21 · How are the same trial, cohorts and time points related?

Current findings: S01 Vidlar2016’s124 participants, three groups, multiple times and two selected sheets share one trial. The S02 observational MID cohort is not urinary-flow/cranberry efficacy replication and is not added as new unique trials or participants.
Verification status: Partly verified
Materials actually read: Stored summary read; external abstracts, full texts, registration, protocols and SAPs unread
Why unverified: The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.
Reason for missing information: Separate replication under the same flow-comparison conditions and independence of study families are not linked.
Required materials and conditions: Overlap among the efficacy trial, threshold cohort and two sheets
Materials to obtain first: Separate replication under the same flow-comparison conditions and independence of study families are not linked.
Further research: Material needed: Separate replication under the same flow-comparison conditions and independence of study families are not linked. This records needed materials; no new research was executed.
Remaining uncertainty: External original material is unread and review of existing content remains incomplete. Original grades, scores, axes, historical verification and independence statements are not treated as new verdicts or certification.
Conditions for verification: Material for Overlap among the efficacy trial, threshold cohort and two sheets must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Why this condition is needed: This condition connects Overlap among the efficacy trial, threshold cohort and two sheets with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

Related sources S01 S02

N22 · Can the six-month results extend to longer periods or other populations?

Current findings: The parent trial lasted six months, while exact objective-test times remain unlinked. Placebo-controlled flow effects are not generalized to other ages/diagnoses or repeated/long-term exposure.
Verification status: Unverified
Materials actually read: Stored summary read; external abstracts, full texts, registration, protocols and SAPs unread
Why unverified: The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.
Reason for missing information: Long-term persistence, population-specific objective effects/denominators and safety are not linked.
Required materials and conditions: Exact objective-test timing, persistence and population-specific direct material
Materials to obtain first: Long-term persistence, population-specific objective effects/denominators and safety are not linked.
Further research: Material needed: Long-term persistence, population-specific objective effects/denominators and safety are not linked. This records needed materials; no new research was executed.
Remaining uncertainty: External original material is unread and review of existing content remains incomplete. Original grades, scores, axes, historical verification and independence statements are not treated as new verdicts or certification.
Conditions for verification: Material for Exact objective-test timing, persistence and population-specific direct material must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Why this condition is needed: This condition connects Exact objective-test timing, persistence and population-specific direct material with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

Related sources S01

N23 · Are prostate size, clinical treatment and ordinary products distinguished?

Current findings: The parent text records that definite prostate-shrinkage or stronger-flow claims exceed scope. Within-group flow/symptom signals are not converted into prostate treatment, prevention, replacement of standard treatment, or effects of ordinary juice/other PAC products.
Verification status: Partly verified
Materials actually read: Stored summary read; external abstracts, full texts, registration, protocols and SAPs unread
Why unverified: The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.
Reason for missing information: Direct material for other clinical questions, products and treatment-replacement comparisons is not linked.
Required materials and conditions: Directness for objective measures versus other questions/products
Materials to obtain first: Direct material for other clinical questions, products and treatment-replacement comparisons is not linked.
Further research: Material needed: Direct material for other clinical questions, products and treatment-replacement comparisons is not linked. This records needed materials; no new research was executed.
Remaining uncertainty: External original material is unread and review of existing content remains incomplete. Original grades, scores, axes, historical verification and independence statements are not treated as new verdicts or certification.
Conditions for verification: Material for Directness for objective measures versus other questions/products must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Why this condition is needed: This condition connects Directness for objective measures versus other questions/products with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

Related sources S01

N24 · What manufacturer employment, support and interests were recorded?

Current findings: The record of two Naturex-employed authors and a branded test product is preserved. This does not substitute for complete funding, free support or COI verification, or a urinary-flow verdict. S02 cohort support is separately unverified.
Verification status: Partly verified
Materials actually read: Stored summary read; external abstracts, full texts, registration, protocols and SAPs unread
Why unverified: The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.
Reason for missing information: Funding roles, product support, employee-author contributions, COI and supporting-cohort support are unverified.
Required materials and conditions: Original employment, product, funding and research-role material
Materials to obtain first: Funding roles, product support, employee-author contributions, COI and supporting-cohort support are unverified.
Further research: Material needed: Funding roles, product support, employee-author contributions, COI and supporting-cohort support are unverified. This records needed materials; no new research was executed.
Remaining uncertainty: External original material is unread and review of existing content remains incomplete. Original grades, scores, axes, historical verification and independence statements are not treated as new verdicts or certification.
Conditions for verification: Material for Original employment, product, funding and research-role material must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Why this condition is needed: This condition connects Original employment, product, funding and research-role material with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

Related sources S01 S02

N25 · What gaps concern safety, laboratory tests and interactions?

Current findings: Parent safety “Unknown” and no six-month clinical-chemistry/hematology change are original statements. No laboratory change is not converted into zero harm or long-term safety; possible warfarin/other interactions are preserved only in their original context.
Verification status: Unverified
Materials actually read: Stored summary read; external abstracts, full texts, registration, protocols and SAPs unread
Why unverified: The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.
Reason for missing information: Direct material on event collection/definitions, group denominators, discontinuation, rare harms and interactions is unverified.
Required materials and conditions: Adverse events, laboratory tests, exposure, denominators and discontinuation
Materials to obtain first: Direct material on event collection/definitions, group denominators, discontinuation, rare harms and interactions is unverified.
Further research: Material needed: Direct material on event collection/definitions, group denominators, discontinuation, rare harms and interactions is unverified. This records needed materials; no new research was executed.
Remaining uncertainty: External original material is unread and review of existing content remains incomplete. Original grades, scores, axes, historical verification and independence statements are not treated as new verdicts or certification.
Conditions for verification: Material for Adverse events, laboratory tests, exposure, denominators and discontinuation must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Why this condition is needed: This condition connects Adverse events, laboratory tests, exposure, denominators and discontinuation with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

Related sources S01

N26 · Were original values, axes, bilingual text, dates and history preserved?

Current findings: Parent C46, B/P/R1/I0/E~/B1, unrecorded precision, four false flags, empty override reasons, and subclaim “?”/note are preserved. Bilingual text,2026-09-07, empty corrections/deliberation and historical effect/scoring checks are not inherited as current review or subclaim scores.
Verification status: Partly verified
Materials actually read: Stored summary read; external abstracts, full texts, registration, protocols and SAPs unread
Why unverified: The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.
Reason for missing information: Subclaim score/status/axes, new corrections and external details of historical checks are unverified.
Required materials and conditions: Distinguishing parent C46, subclaim “?”, corrections and historical checks
Materials to obtain first: Subclaim score/status/axes, new corrections and external details of historical checks are unverified.
Further research: Material needed: Subclaim score/status/axes, new corrections and external details of historical checks are unverified. This records needed materials; no new research was executed.
Remaining uncertainty: External original material is unread and review of existing content remains incomplete. Original grades, scores, axes, historical verification and independence statements are not treated as new verdicts or certification.
Conditions for verification: Material for Distinguishing parent C46, subclaim “?”, corrections and historical checks must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Why this condition is needed: This condition connects Distinguishing parent C46, subclaim “?”, corrections and historical checks with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

Related sources S01 S02

N27 · What was actually read, and what follow-up material is needed?

Current findings: S01 efficacy/objective-outcome statements and the S02 MID citation were used for production, retaining original links. External abstracts, full texts, registration, protocols, SAPs and COI material are unread and were not accessed.
Verification status: Partly verified
Materials actually read: Stored summary read; external abstracts, full texts, registration, protocols and SAPs unread
Why unverified: The selected claim, parent material and reports are distinguished and transferred from the stored summary. Detailed original material is unverified and review of existing content remains incomplete. This does not establish completed clinical review or certification.
Reason for missing information: Report-specific originals, registration, plans, support material, actual external reading and follow-up content review remain incomplete.
Required materials and conditions: Stored-summary use, unread external material and update scope
Materials to obtain first: Report-specific originals, registration, plans, support material, actual external reading and follow-up content review remain incomplete.
Further research: Material needed: Report-specific originals, registration, plans, support material, actual external reading and follow-up content review remain incomplete. This records needed materials; no new research was executed.
Remaining uncertainty: External original material is unread and review of existing content remains incomplete. Original grades, scores, axes, historical verification and independence statements are not treated as new verdicts or certification.
Conditions for verification: Material for Stored-summary use, unread external material and update scope must be linked to the selected subclaim, parent context, original report, time points, comparator and denominators, distinguishing unread external material.
Why this condition is needed: This condition connects Stored-summary use, unread external material and update scope with the selected question, actual population, test product, comparator, symptom scale, objective outcomes, time points, denominators and harms.
Application exceptions: Preserve original numbers while distinguishing total IPSS/subscores/QoL, objective flow/residual urine/prostate size, group changes/placebo contrasts/between-dose comparisons, MID sources and individual/group interpretation, timing, denominators, products, harms and unread external material. No new calculations, hypothetical examples, effects, CIs, regrading, independence certification, product intake, urinary/prostate treatment, prevention or treatment-replacement advice is created.
Referenced methods: Preserved C/E/H application conditions concerning questions, populations, interventions, comparators, reports versus studies, endpoints, denominators and harms were referenced.

Related sources S01 S02